Risk factors
20/20 Biolabs (AIDX) risk factors
Item 1A of every 20/20 Biolabs, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors48 risks
Profitability achieved in 2021 and 2022 relied on COVID-19 testing that ceased in Q2 2023. Commercial success heavily depends on cancer screening and longevity tests. Operations face high risks regarding capital needs, regulatory changes like FDA LDT rules, and patent protection.
Filed Mar 31, 2026